Farallon Capital Partners L.P. 13D and 13G filings for Beam Therapeutics Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-11-07 09:56 am Purchase | 2024-09-30 | 13G | Beam Therapeutics Inc. BEAM | Farallon Capital Partners L.P. | 8,208,123 9.900% | 4,102,370 (+99.92%) | Filing |
| 2024-02-12 3:38 pm Sale | 2023-12-31 | 13G | Beam Therapeutics Inc. BEAM | Farallon Capital Partners L.P. | 4,105,753 5.000% | -7,716 (-0.19%) | Filing |
| 2023-09-22 3:20 pm Purchase | 2023-09-13 | 13G | Beam Therapeutics Inc. BEAM | Farallon Capital Partners L.P. | 4,113,469 5.200% | 713,548 (+20.99%) | Filing |
| 2023-02-14 08:27 am Sale | 2022-12-31 | 13G | Beam Therapeutics Inc. BEAM | Farallon Capital Partners L.P. | 3,399,921 4.800% | -151,850 (-4.28%) | Filing |
| 2022-07-14 3:55 pm Purchase | 2022-07-05 | 13G | Beam Therapeutics Inc. BEAM | Farallon Capital Partners L.P. | 3,551,771 5.100% | 3,551,771 (New Position) | Filing |